FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily

oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Sumanta K. Pal: Beautiful Articulation of How We Can Personalize Therapy for Advanced Prostate Cancer

2 months / oncodaily

NanoKnife Success Rate for Prostate Cancer. What Patients Need to Know in 2026

2 months / oncodaily

Neal Shore: Efficacy and Safety of Treatments for Metastatic Castration-Sensitive Prostate Cancer

2 months / oncodaily

How testosterone went from prostate cancer villain to potential ally

2 months / medicalxpress

Pasritamig (JNJ-78278343): A Patient Guide To A New Immunotherapy For Advanced Prostate Cancer

2 months / oncodaily

Pasritamig (JNJ-78278343): A Next-Generation T-Cell Engager for Metastatic Castration-Resistant Prostate Cancer

2 months / oncodaily

AMPLITUDE Trial: Niraparib Plus Abiraterone in HRR-Mutated mCSPC

2 months / oncodaily

Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO)

2 months / nature

Accelerated cancer drug approvals yield modest survival gains at significant Medicare cost

2 months / medicalxpress

Liang Cheng: Great Honor to Have Contributed 3 Articles to the Special Issue in Urologic Oncology

2 months / oncodaily

Axel S. Merseburger: Insights on ARLDDs and the rechARge Study for mCRPC

2 months / oncodaily

FDA approves prostate cancer drug

2 months / beckershospitalreview / Ella Jeffries

FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

2 months / oncodaily

Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months

Related Stories

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 2 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 3 months
FDA Approves Ziftomenib for AML Treatment / 3 months
FDA updates Sarepta gene therapy label with severe warnings / 3 months
Experimental therapy reduces seizures in children with Dravet syndrome / 5 days

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Public Health

Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #publichealth

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.